Hospital Pharmacy - October 2019 - 331

331

Sabins et al
actual concentrations would be slightly lower due to bag
overfill and additive volume. The purpose of this study was
to evaluate the stability and compatibility of 0.2 and 1.0 mg/
mL diphenhydramine HCl admixtures in 0.9% sodium chloride injection and 5% dextrose injection in polyvinyl chloride (PVC) IV bags stored under refrigeration (2°C-8°C) for
up to 14 days.

Table 1. Forced Degradation Study of Diphenhydramine HCl.
Sample No.
1
2
3
4

Stress conditions

% drug remaining
after 24 hours

pH 2 and 60°C
pH 12 and 60°C
3% H2O2 and 60°C
3% H2O2 and sunlight

82.3
94.8
6.6
18.9

Methods
Materials for IV Admixtures
Diphenhydramine HCl Injection, USP, 50 mg/mL, and 1-mL
vials were purchased from Fresenius Kabi (NDC no. 63323664-16; lot no. 6011913; Lake Zurich, IL). The diluents used
to prepare the IV admixtures were obtained from 250 mL bags
of 0.9% Sodium Chloride Injection, USP, from Baxter (NDC
no.0338-0049-02, lot no. Y234302; Deerfield, IL) and 5%
Dextrose Injection, USP, from Baxter (NDC no.0338-001702, lot no. Y228320). Sterile empty 50 mL IV bags were not
available commercially at the time of the study. Therefore, 50
mL bags of 0.9% Sodium Chloride Injection, USP (NDC
no.0338-0049-31, lot no. P360990) and 5% Dextrose Injection,
USP (NDC no.0338-0017-11, lot no. P349647) were purchased from Baxter. The fluid in each 50 mL bag was completely removed under aseptic conditions prior to packaging of
the stability samples. The material of these bags was PVC.

Materials for High-Performance Liquid
Chromatography Analysis
A Milli-Q Direct 8 system from Millipore Sigma (Burlington,
Massachusetts) was used to produce Type I (ultrapure) water.
Acetonitrile and trifluoroacetic acid, both high-performance
liquid chromatography (HPLC) grades, were purchased from
Thermo Fisher Scientific (Waltham, Massachusetts).
Diphenhydramine HCl powder (99% purity) was purchased
from Acros Organics (Cat no. AC350850250, lot no.
A0370928; Pittsburgh, PA) and used as a reference standard
for HPLC calibration purpose.

Scientific Instruments (Marlborough, Massachusetts) was
equipped with a C18, 3 µm, 100 A, 4.6×150 mm column
from Phenomenex (Torrance, California) as the stationary
phase. The mobile phase consisted of water:acetonitrile
(63:37) with 0.1% trifluoroacetic acid, and the pH was
approximately 2.0. Additional instrument parameters were
set as follows: column temperature at 40°C, mobile phase
flow rate of 0.6 mL/min, sample injection volume of 5 µL,
and ultraviolet detection at 220 nm. Data collection and processing were performed by the Shimadzu LC Solution
software.
For calibration purpose, 5 standard solutions of diphenhydramine HCl (0.16, 0.18, 0.20, 0.22, and 0.24 mg/mL)
were run on each analysis day. This range encompasses the
80% to 120% of the expected concentration of the HPLC
samples. These standards were prepared from the pure
diphenhydramine HCl powder dissolved in water. A calibration curve was constructed on each analysis day by plotting
the peak area against concentration. The midpoint standard
of 0.20 mg/mL was also injected 3 times on each analysis
day to monitor the intraday and interday variability of the
HPLC method.

Forced Degradation Study

A Mettler-Toledo SevenEasy model pH meter (Columbus,
Ohio) was used with a gel-filled pencil-thin pH electrode
from Fisher Scientific (Cat no. 13-620-290). The pH meter
was calibrated daily with standard pH 4 and 7 buffer solutions purchased from Fisher Scientific (Cat no. SB101-500
and SB107-500).

A forced degradation study was performed to confirm that
the above HPLC method could separate the potential degradation products from the original drug. As listed in Table 1, 4
drug samples of 0.20 mg/mL were subjected to different
stress conditions of extreme pH, oxidizing agent, heat, and
light. Samples 1 and 2 were adjusted to pH 2 and pH 12 by
adding 1 M hydrochloric acid and 1 M sodium hydroxide,
respectively. Samples 3 and 4 were both spiked with concentrated hydrogen peroxide to a final concentration of 3%.
Samples 1, 2, and 3 were incubated at 60°C, and Sample 4
was exposed to direct sunlight at ambient room temperature.
All 4 samples were monitored by the HPLC analysis until a
minimum of 10% degradation was observed in at least 1 of
the 4 samples.10,11

HPLC Analysis

14-Day Stability Study of IV Admixtures

A reversed-phase HPLC method was developed for diphenhydramine to measure drug concentration and monitor drug
stability. A Model LC-2010A system from Shimadzu

Four IV admixtures of diphenhydramine were prepared for
this stability study which included 2 drug concentrations
(0.2 and 1.0 mg/mL) and 2 diluents (0.9% sodium chloride

pH Analysis



Hospital Pharmacy - October 2019

Table of Contents for the Digital Edition of Hospital Pharmacy - October 2019

TOC/Verso
Disrespectful Behavior in Health System Pharmacy Practice: Consequences and Next Steps
The Orphan Drug Act: An Appropriate Approval Pathway for Treatments of Rare Diseases?
Significant Published Articles for Pharmacy Nutrition Support Practice in 2018
Impact of Delayed Oral Vancomycin for Severe Clostridium difficile Infection
Evaluation of a Hospital Pharmacist Annual Competency Program
A Retrospective Analysis of Adherence to Risk Evaluation and Mitigation Strategies Requirements for Pulmonary Arterial Hypertension Drugs
Impact of an Advanced Pharmacy Practice Experience Student-Run “Meds 2 Beds” and Discharge Counseling Program on Quality of Care
A Retrospective Surveillance of the Antibiotics Prophylactic Use of Surgical Procedures in Private Hospitals in Indonesia
Stability and Compatibility of Diphenhydramine Hydrochloride in Intravenous Admixtures: A New Look at an Old Drug
The Impact of an Automated Dispensing System for Supplying Narcotics in a Surgical Unit: The Experience of the National Cancer Institute Foundation of Milan
Hospital Pharmacy - October 2019 - Cover1
Hospital Pharmacy - October 2019 - Cover2
Hospital Pharmacy - October 2019 - 277
Hospital Pharmacy - October 2019 - TOC/Verso
Hospital Pharmacy - October 2019 - 279
Hospital Pharmacy - October 2019 - Disrespectful Behavior in Health System Pharmacy Practice: Consequences and Next Steps
Hospital Pharmacy - October 2019 - 281
Hospital Pharmacy - October 2019 - 282
Hospital Pharmacy - October 2019 - The Orphan Drug Act: An Appropriate Approval Pathway for Treatments of Rare Diseases?
Hospital Pharmacy - October 2019 - 284
Hospital Pharmacy - October 2019 - Significant Published Articles for Pharmacy Nutrition Support Practice in 2018
Hospital Pharmacy - October 2019 - 286
Hospital Pharmacy - October 2019 - 287
Hospital Pharmacy - October 2019 - 288
Hospital Pharmacy - October 2019 - 289
Hospital Pharmacy - October 2019 - 290
Hospital Pharmacy - October 2019 - 291
Hospital Pharmacy - October 2019 - 292
Hospital Pharmacy - October 2019 - 293
Hospital Pharmacy - October 2019 - Impact of Delayed Oral Vancomycin for Severe Clostridium difficile Infection
Hospital Pharmacy - October 2019 - 295
Hospital Pharmacy - October 2019 - 296
Hospital Pharmacy - October 2019 - 297
Hospital Pharmacy - October 2019 - 298
Hospital Pharmacy - October 2019 - 299
Hospital Pharmacy - October 2019 - Evaluation of a Hospital Pharmacist Annual Competency Program
Hospital Pharmacy - October 2019 - 301
Hospital Pharmacy - October 2019 - 302
Hospital Pharmacy - October 2019 - 303
Hospital Pharmacy - October 2019 - 304
Hospital Pharmacy - October 2019 - 305
Hospital Pharmacy - October 2019 - 306
Hospital Pharmacy - October 2019 - 307
Hospital Pharmacy - October 2019 - 308
Hospital Pharmacy - October 2019 - A Retrospective Analysis of Adherence to Risk Evaluation and Mitigation Strategies Requirements for Pulmonary Arterial Hypertension Drugs
Hospital Pharmacy - October 2019 - 310
Hospital Pharmacy - October 2019 - 311
Hospital Pharmacy - October 2019 - 312
Hospital Pharmacy - October 2019 - 313
Hospital Pharmacy - October 2019 - Impact of an Advanced Pharmacy Practice Experience Student-Run “Meds 2 Beds” and Discharge Counseling Program on Quality of Care
Hospital Pharmacy - October 2019 - 315
Hospital Pharmacy - October 2019 - 316
Hospital Pharmacy - October 2019 - 317
Hospital Pharmacy - October 2019 - 318
Hospital Pharmacy - October 2019 - 319
Hospital Pharmacy - October 2019 - 320
Hospital Pharmacy - October 2019 - 321
Hospital Pharmacy - October 2019 - 322
Hospital Pharmacy - October 2019 - A Retrospective Surveillance of the Antibiotics Prophylactic Use of Surgical Procedures in Private Hospitals in Indonesia
Hospital Pharmacy - October 2019 - 324
Hospital Pharmacy - October 2019 - 325
Hospital Pharmacy - October 2019 - 326
Hospital Pharmacy - October 2019 - 327
Hospital Pharmacy - October 2019 - 328
Hospital Pharmacy - October 2019 - 329
Hospital Pharmacy - October 2019 - Stability and Compatibility of Diphenhydramine Hydrochloride in Intravenous Admixtures: A New Look at an Old Drug
Hospital Pharmacy - October 2019 - 331
Hospital Pharmacy - October 2019 - 332
Hospital Pharmacy - October 2019 - 333
Hospital Pharmacy - October 2019 - 334
Hospital Pharmacy - October 2019 - The Impact of an Automated Dispensing System for Supplying Narcotics in a Surgical Unit: The Experience of the National Cancer Institute Foundation of Milan
Hospital Pharmacy - October 2019 - 336
Hospital Pharmacy - October 2019 - 337
Hospital Pharmacy - October 2019 - 338
Hospital Pharmacy - October 2019 - 339
Hospital Pharmacy - October 2019 - 340
Hospital Pharmacy - October 2019 - 341
Hospital Pharmacy - October 2019 - 342
Hospital Pharmacy - October 2019 - 343
Hospital Pharmacy - October 2019 - 344
Hospital Pharmacy - October 2019 - Cover3
Hospital Pharmacy - October 2019 - Cover4
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_december2020
https://www.nxtbook.com/nxtbooks/sage/psychologicalscience_demo
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_october2020
https://www.nxtbook.com/nxtbooks/sage/fai_202009
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_august2020
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_june2020
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_april2020
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_february2020
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_december2019
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_october2019
https://www.nxtbook.com/nxtbooks/sage/fai_201909
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_july2019
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_june2019
https://www.nxtbook.com/nxtbooks/sage/canadianpharmacistsjournal_05062019
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_april2019
https://www.nxtbook.com/nxtbooks/sage/sri_supplement_201903
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_february2019
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_december2018
https://www.nxtbook.com/nxtbooks/sage/tec_20180810
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_october2018
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_julyaugust2018
https://www.nxtbook.com/nxtbooks/sage/fai_201807
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_june2018
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_april2018
https://www.nxtbook.com/nxtbooks/sage/sri_supplement_201803
https://www.nxtbook.com/nxtbooks/sage/slas_discovery_201712
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_february2018
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_december2017
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_november2017
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_october2017
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_september2017
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_julyaugust2017
https://www.nxtbook.com/nxtbooks/sage/fai_supplement_201709
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_june2017
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_may2017
https://www.nxtbook.com/nxtbooks/sage/fai_201706
https://www.nxtbook.com/nxtbooks/sage/fai_201607
https://www.nxtbookmedia.com